 |
Ashvattha Therapeutics
Last updated: May 01, 2024
Founder Jeffrey Cleland
Country: USA | Funding: $98M (+)
Website: http://avttx.com/
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
Website: http://avttx.com/
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.